In 2004, the American Association of Clinical Endocrinologists (AACE) published the "Protocol for Standardized Production of Clinical Practice Guidelines," which was to be implemented in forthcoming clinical practice guidelines (CPG). This protocol formally incorporated subjective factors and evidence-based medicine (EBM) methods that tightly mapped evidence levels to recommendation grades. A uniform publication template and multilevel review process were also outlined. Seven CPG have been subsequently published with use of this 2004 AACE protocol. Recently, growing concerns about the usefulness of CPG have been raised. The purposes of this report are to address shortcomings of the 2004 AACE protocol and to present an updated 2010 AACE protocol for CPG development. AACE CPG are developed without any industry involvement. Multiplicities of interests among writers and reviewers that might compromise the usefulness of CPG are avoided. Three major goals are to (1) balance transparently the effect of rigid quantitative EBM methods with subjective factors, (2) create a less onerous, less time-consuming, and less costly CPG production process, and (3) introduce an electronic implementation component. The updated 2010 AACE protocol emphasizes "informed judgment" and hybridizes EBM descriptors (study design type), qualifiers (study flaws), and subjective factors (such as risk, cost, and relevance). In addition, by focusing on more specific topics and clinical questions, the expert evaluation and multilevel review process is more transparent and expeditious. Lastly, the final recommendations are linked to a new electronic implementation feature. (Endocr Pract. 2010;16:270-283) Abbreviations: AACE = American Association of Clinical Endocrinologists; CIG = computer-interpretable guidelines; CPG = clinical practice guidelines; DOE = disease-oriented evidence; EBM = evidence-based medicine; GRADE = Grading of Recommendations, Assessment, Development, and Evaluation; POEMS = patient-oriented evidence that matters
INTRODUCTION
In 2004, the American Association of Clinical Endocrinologists (AACE) published the "Protocol for Standardized Production of Clinical Practice Guidelines" ("2004 AACE protocol") (1) . That report outlined (1) the need for evidence-based medicine (EBM) clinical practice guidelines (CPG), (2) attributes of successful CPG, (3) a document template, (4) a specific method for evidence rating, incorporation of subjective variables, and transparent formulation of recommendation grades, and (5) a rigorous multilevel review process (1) . The mandate for this document resulted from the increased number of AACE CPG being published without a consistent methodologic approach to provide an EBM recommendation. The major issues confronting AACE CPG task forces before 2004 were related to the controversies surrounding various EBM methods and how to distinguish EBM CPG from other types of publications, such as "white papers," clinical algorithms, road maps, consensus reports, opinion papers, position papers, conference proceedings, technical reviews, and review articles. Before the existence of the 2004 AACE protocol, there were 19 published AACE CPG documents, of which 18 were consensus reports-leaving only 1 that used EBM technical review procedures (2) . Subsequently, and after a 1-year hiatus to reengineer CPG already in progress, 7 AACE CPG were published, all of which were in strict adherence with the 2004 AACE protocol (Table 1) .
Since 2004, important advances have been made in the area of CPG development. First, and probably most importantly, is the popularization of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system, which has been extensively discussed in the literature (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) and subsequently garnered acceptance from a host of medical societies, including The Endocrine Society (13) (14) (15) . Attributes of the GRADE system and other EBM methodologies are outlined in Table 2 . After a review of these methodologies, however, it would appear that an optimal CPG strategy might not be entirely evidence-based. Hence, an improved CPG would merge the elements of scientific substantiation with elements of transparency, intuitiveness, subjective factors, and relevance. In addition, shortcomings of evidence-based methods should be addressed, such as being too complex, using imprecise terms ("semantic imprecision"), and being too costly and labor-intensive to adapt and implement.
What constitutes the major difference between the 2004 AACE protocol and other current CPG protocols is the EBM methodology. The 2004 AACE protocol EBM methodology was outlined in Table 2 of the original reference (1) and is based on similar evidence ratings and recommendation grades used by the American Diabetes Association, the National Heart, Lung, and Blood Institute, and the American Gastroenterological Association. Furthermore, it incorporates many of the attributes of other CPG methodologies summarized in Table 2 , herein. The 2004 AACE protocol incorporates 4 intuitive evidence levels (strong, intermediate, weak, or none) based on research methodology and stresses an explicit and rigid numerical descriptor. These evidence levels are then discussed among the CPG authors, and various subjective factors are incorporated as needed, such as risk-benefit analysis, cost-benefit analysis, clinical relevance, and others. A final quantitative recommendation grade for DOING an action or NOT DOING an action is then determined. This is almost always linearly mapped to the best evidence level. Any deviations in this mapping are explicitly described and explained. The advantage of this evidence rating-grade recommendation protocol is the intuitive simplicity (strong, intermediate, weak, or none).
Growing criticisms still surround CPG in the medical literature. Important issues, such as cost-containment, geographic variations in resource availability, industry involvement, conflicts or multiplicities of interest, bias, paucity of credentialed authors, and time limitations, plague professional medical societies and produce CPG results that may not be credible or reproducible (27) . This situation creates confusion and mitigates the intended benefit of CPG: to foster a consistent practice of high-quality medicine. In addition, the notion that evidence must be rated in accordance with some rigid hierarchy might be misguided. For example, in a recent article in The Lancet, Rawlins (28) pointed out that the presumed "gold standard" of clinical evidence-a randomized controlled trial-has many pitfalls. Foremost among these pitfalls are nongeneralizability and overdependence on non-Bayesian statistical analysis (see Appendix for Glossary of Terms).
Even more problems exist. Systematic literature searches are subject to study publication and reporting biases, in which medical journals are more likely to publish studies with positive findings rather than negative findings (29, 30) . Other issues that mitigate clinical evidence in medical decision making are stopping randomized controlled trials early because of apparent benefit (31) , poor overall quality of meta-analyses (32, 33) , failure to include adequate intent-to-treat analysis (30, 34) , allocation concealment (randomization), and appropriate "blinding" (30) . Tricoci et al (35) highlighted the impact and dominance of flawed and "weak" studies on CPG. On analysis of the evolution of CPG recommendations by the American College of Cardiology and American Heart Association, they concluded that improved CPG methodologies will need to address the effect of a surplus of lower levels of evidence.
Current protocols for literature searching may also fail to account for complex interactions among multiple interventions. Additionally, there are complexities that result from social networks among caregivers and other clinical practice idiosyncrasies that account for differences between "real-world" outcomes and "proof-of-concept" outcomes. Incorporation of other sources of complexity, physiologic and pharmacologic, is now being addressed by using a systems biology approach to clinical medicine (see Appendix). Simply typing keywords into a search engine, and then performing an analysis, will potentially miss important, clinically relevant complex interactions. Shepperd et al (36) examined this problem and proposed the formulation of middle-range theory to guide literature searching (see Appendix).
Systematic literature searching should also be able to gauge clinical relevance (37) (38) (39) (40) . "Disease-oriented evidence" (DOE)-research focusing on intermediate or surrogate outcomes-dominates the medical literature and arguably misinforms clinical decision making (36) . This is distinguished from "patient-oriented evidence that matters" (POEMs), in which, with little extrapolation, clinicians can easily derive information about diagnostic, therapeutic, or preventive procedures that help patients live longer or better (37) . POEMs is considered highly relevant and valid information. Examples in the endocrinology literature include (1) fluoride therapy increasing bone mineral density in postmenopausal women with osteoporosis (DOE) versus fluoride therapy increasing nonvertebral fractures (POEMs) and (2) weight gain occurring in patients in the United Kingdom Prospective Diabetes Study (except those treated with metformin) (DOE) versus quality of life not being affected, positively or negatively, by tight blood glucose control (POEMs) (36) . Although various position papers supporting the use of POEMs have had little effect on the predominance of DOEs in the medical literature, these position papers raise a valid point that CPG need to be relevant to actual clinical problems. Furthermore, by incorporating POEMs, CPG move closer to truly hybridizing EBM with medical humanism (41) .
ThE UPDATED 2010 AACE PROTOCOl
Currently, chairpersons and primary writers actively involved in AACE CPG task forces have had several years of experience with the 2004 AACE protocol. Three general categories of shortcomings have been articulated and serve as the impetus for the updated 2010 AACE protocol: methodology, review process, and implementation.
The 4-Step EBM Methodology
The entire AACE CPG development process is conducted free of industry involvement. Once the CPG topic is assigned, the chairperson and primary writers are identified. Then middle-range theories are generated that will guide the systematic literature search. Once this has been completed, there are 4 sequential steps in the integration of clinical evidence into recommendation grades:
• Step I: evidence rating based on methodology • Step II: analysis of evidence and identification of subjective factors • Step III: phrasing, determining level of consensus, and alphabetic grading of recommendations • Step IV: appending qualifiers to recommendations
In the first step, credentialed experts on the writing committee assign numerical and semantic descriptors to the clinical evidence (Table 3 ). In the second step, comments are provided regarding evidentiary strengths and weaknesses (Table 4 ). In the third step, recommendations are phrased and discussed, levels of consensus are determined, and recommendation grades are conferred (Table  5 ). Relevant dissenting opinions can be briefly and explicitly provided in the Appendix section of the CPG. The recommendation phraseology will be engineered in the 2010 AACE protocol to create a clinical algorithm that reflects the process flow of the clinical encounter and can be used in the electronic implementation component to reduce errors (42, 43) . Nodes in the clinical algorithm will be numbered and then explicitly linked with graded recommendations in the Executive Summary and the evidence base in the Appendix section of the CPG (44, 45) . In the fourth and final step, miscellaneous qualifiers are considered that were not incorporated as subjective factors to determine the recommendation grade but are still deemed important (Table 6 ). An explicit description of these miscellaneous attributes of the evidence base and the subsequent expert discussion are provided in the Appendix section of the CPG in an effort to optimize transparency.
An optional procedural step may be appended to the recommendations in step IV if the experts conclude that alternative recommendations can be formulated. These alternatives may be due to variations of resource availability and cultural factors in different geographic areas. An alternative graded recommendation would be provided in the Executive Summary, and the rationale would be inserted in the Appendix. In other words, globally relevant recommendation "cascades" (46) are produced, which can broaden the utility and applicability of specific recommendations around the world, based on economic and educational differences. For instance, the routine evaluation of thyroid nodules may not necessitate ultrasonography in some countries that cannot afford the widespread purchase of ultrasound equipment or in which there is a shortage of experienced thyroid ultrasonographers.
Transparency for this 4-step methodology will be realized by maintaining a record of the CPG development process. Aron and Pogach (47) reviewed the importance of transparency as applied to the divergent EBM recommendations for target hemoglobin A1c levels in diabetes.
Unfortunately, transparency is confounded by semantic imprecision and is a common shortcoming among all protocols in Table 2 . In other words, human language is still relatively imprecise when technical concepts, human subjectivities, and vague or ambiguous terms are being described. Accordingly, despite the best intentions, the concept of full transparency is untenable. The 2010 AACE protocol addresses semantic imprecision by (1) using a controlled medical vocabulary in the recommendation phraseology for easy adaptation into computer-interpretable guidelines (CIG) (48) (49) (50) (51) and (2) Table 7 .
Review Process
The multilevel review process requires iterations of review by the chairperson and primary writers after each revision by assigned "reviewers," the AACE Publications Committee, the AACE Board of Directors, and, finally, the editorial process of Endocrine Practice. Special reviewers "first-in-its-class" intervention) Sample size (beta error) Null hypothesis versus Bayesian statistics (non-AACE members) may be invited to participate in the review process. All authors and reviewers will be selected on the basis of expert credentials covering the topic (or topics) of interest, absence of any multiplicity of interests that would compromise the usefulness of the CPG, and commitment to complete their assignments according to the stated timeline. This review process will be expedited by selecting topics that are amenable to an abbreviated (6-month) timeline. This can be accomplished by focusing on more specific topics and by using a question-oriented approach and theory-driven literature search.
Implementation
Implementation of CPG adherent with the 2010 AACE protocol will include the following factors:
1. Development of continuing medical education credit linked to the reading of and correct responses to questions on the content of the CPG a Starting with the left column, best evidence levels (BEL), subjective factors, and consensus map to recommendation grades in the right column. When subjective factors have little or no impact ("none"), then the BEL is directly mapped to recommendation grades. When subjective factors have a strong impact, then recommendation grades may be adjusted up ("positive" impact) or down ("negative" impact). If a twothirds consensus cannot be reached, then the recommendation grade is D. NA = not applicable (regardless of the presence or absence of strong subjective factors, the absence of a two-thirds consensus mandates a recommendation grade D). Primary literature search By primary writers By primary writers with assistance by AACE staff; will be guided by middle-range theories to account for complex interactions in patient management
Step I (see Table 3 Step II (see Table 4 ) No comments based on study flaws Subjective factors are provided as annotations in reference section and may also be discussed in Appendix: for example, [EL 1; RCT; small sample size (N = 12) with selection bias and not generalizable to patients >65 years old]
Step III (see Table 5 Step IV (see Table 6 ) Additional qualifiers not given Additional qualifiers are part of annotation in reference section and may also be discussed in Appendix: for example, [RCT; EL 1; small sample size (N = 12) with selection bias and not generalizable; study is relevant but intervention is costly; cost-effectiveness analysis not reported] 2. Distribution of surveys to AACE membership regarding the relevance and utility of the CPG and then incorporation of responses into CPG updates 3. Development of electronic implementation of clinical knowledge management systems that are evidence-based and can be integrated with electronic medical records and other health care information systems
CONClUSION
AACE is committed to enhancing the ability of clinical endocrinologists to provide the highest quality of medical care and improve public health. In fulfilling this AACE mission, CPG can be invaluable assets. The metamorphosis of CPG from informal, biased, opinion papers and consensus reports into formalized EBM documents may now evolve further. Moving forward, AACE CPG will be userfriendlier and more transparently developed. They will hybridize hard evidence, soft experience-based impressions, and pragmatic implementation tools for the electronic age of medicine. Ultimately, the target is a clinical decision support system (52) emphasizing "informed judgment," in which science, beliefs, and computerization are each necessary, but not sufficient, components. Examples include, but are not limited to, CIG (53), "neuro-fuzzy systems" (54) , and Bayesian networks (55) .
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APPENDIx: GlOSSARY OF TERMS
Allocation concealment. Prevention of the next assignment in a clinical trial from being known; necessary for randomization.
Bayesian network.
A decision-theoretic model that can express conditional dependencies in a manner that is both accessible to humans and comprehensible to computers. Accessibility to humans refers to availability over the Internet, or other computer-based system, and in a language that is understandable.
Bayesian statistics. Method in which new assumptions about parameters are continually revised on the basis of new sample data and a synthesis of information about previous assumptions ("prior distribution"). "Degrees of belief" or levels of certainty-which are subject to change as more evidence emerges-that a hypothesis is correct are used instead of numerical frequencies, which are used in non-Bayesian statistics. The use of Bayesian statistics is important during evaluation, for example, of the probability that a positive test result is a false positive, which is critically important in determining the utility of a diagnostic test for a rare disease.
Beta error. A form of statistical error ("of the second kind" or type II)-concluding that something is negative when it actually is positive (a "false negative"). Beta error is a function of sample size, among other variables.
Blinding. In single-blind clinical studies, the study subjects are not aware of the treatment they are receiving. In doubleblind clinical studies, the researchers and the subjects are unaware of which treatment is allocated to whom. Blinding is used to prevent bias in clinical research.
Clinical algorithm. A step-by-step procedure for solving a clinical problem with use of conditional "if/then" logic statements.
Clinical decision-support systems. Systems that aid clinicians in gathering relevant data, making clinical decisions, and managing medical actions more effectively.
Clinical knowledge management systems. Systems that help health care organizations use practices that, through more effective utilization of their knowledge assets, increase the competitive advantage of an organization in a highly dynamic environment. Such systems are applicable in a setting where medical knowledge changes rapidly and where health care providers and patients interact in distributed and collaborative processes. Distributed processes refer to a network of coordinated centers that provide complementary services in different locations-ranging from the highly complex such as referral hospitals to the less complex such as solo practices.
Clinical practice guidelines (CPG).
Systematically developed documents that assist practitioners make appropriate health care decisions for specific clinical problems.
Computer-interpretable guidelines (CIG).
A guideline representation that is accessible to humans and supports computer-based execution that requires automatic inference. CIGs can deliver patient-specific knowledge at the point of care during clinical encounters.
Controlled medical vocabulary.
A list of term identifiers that disambiguate words used in clinical practice and the medical literature.
Evidence-based medicine (EBM).
A learning strategy. The deliberate use of clinical evidence in the care of individual patients and composed of 4 parts: formulating a clinical question from a patient's problem, searching the medical literature for relevant clinical publications, critically appraising the evidence for validity and usefulness, and implementing useful findings in clinical practice.
Intent-to-treat. Pertaining to clinical trials: based on the initial treatment allocation and not the treatment that was eventually administered.
